Garofalo Health Care has closed the acquisition of Casa di Cura Malatesta Novello (Cesena) for EUR 69.3 million, reinforcing its position in Emilia-Romagna as Italian healthcare groups push consolidation among private accredited operators.
Why this deal, why now
For Garofalo, the logic is consistent with its stated view of the market: regulation, economies of scale and generational succession are accelerating M&A among private providers accredited with the National Healthcare Service (SSN). The group has also cited rising pressure on smaller operators that cannot capture scale benefits, a dynamic that continues to create willing sellers.
The Malatesta Novello acquisition fits that playbook. Reported coverage of the transaction indicates it would lift Garofalo’s Emilia-Romagna revenue to around EUR 200 million, signalling a deliberate effort to build a denser regional base rather than a one-off asset purchase.
Deal context
The announcement lands against a backdrop of sustained deal activity in Italian healthcare. Healthcare investment in Italy reached EUR 270 million in Q2 2025, driven entirely by three portfolio transactions, including ENPAM’s acquisition of 10 clinics and one RSA. Separately, institutional appetite for healthcare property has remained visible, including a 2025 BNP Paribas REIM deal for a majority stake in a portfolio of 23 Italian healthcare properties valued above EUR 300 million.
While not every transaction bundles operations and property, recent precedents show real estate can be part of the structuring. Garofalo’s July 2025 acquisition of Casa di Cura Città di Roma (announced July 2025, completed January 2026) included the target’s real-estate assets of roughly 8,000 square meters and was positioned as synergistic with the group’s existing hospitals.
Strategic lens: what Garofalo is underwriting
This acquisition extends Garofalo’s regional platform, with the key underwriting question being whether it can translate incremental scale into measurable operational gains without disrupting clinical performance.
Key areas the market will focus on include:
- Integration capacity and governance: aligning clinical pathways, quality standards, procurement and back-office processes while maintaining accreditation requirements.
- Go-to-market overlap and referral patterns: whether Malatesta Novello adds complementary specialties or introduces internal competition with existing facilities in the region.
- Capex and throughput discipline: Garofalo is expanding while broader healthcare investors remain active, so execution will hinge on prioritising investments that improve utilisation and service mix rather than simply adding beds.
- Leadership depth: consolidation in accredited healthcare often stresses local management bandwidth. The ability to retain and motivate clinical leadership is typically decisive.
Emilia-Romagna as a consolidation battleground
The deal also underlines platform-building momentum in Emilia-Romagna. Prevenzione e Salute Holding, for example, has pursued targeted acquisitions and organic growth with a predominant presence in the region. The available evidence does not provide a market-wide concentration measure, but activity levels point to a competitive race to assemble scaled networks that can absorb regulatory complexity and negotiate from a stronger operational base.
What to watch next
- Integration plan and timelines, including any changes to service lines, governance or leadership at Malatesta Novello.
- Capex priorities following the acquisition and how investment is split between capacity, technology and facility upgrades.
- Further bolt-ons in Emilia-Romagna, as Garofalo moves from footprint expansion to density-building.
- Evidence of operating synergies, particularly in procurement, shared services and clinical pathway standardisation.